Cardiovascular Outcome Trials with Glucose-Lowering Drugs

Purpose of Review This review summarizes recent cardiovascular outcome trials (CVOTs) with glucose-lowering drugs. Recent Findings The majority of recent CVOTs with glucose-lowering drugs have tested dipeptidyl peptidase-4 inhibitors (DPP4-i), glucagon-like peptide-1 receptors agonists (GLP1-RA), an...

Full description

Saved in:
Bibliographic Details
Published in:Current cardiology reports 2021-07, Vol.23 (7), p.75-75, Article 75
Main Authors: Thethi, Tina K., Bilal, Anika, Pratley, Richard E.
Format: Article
Language:English
Subjects:
Cardiology
Diabetes and Cardiovascular Disease (D Bruemmer
Medicine
Medicine & Public Health
Section Editor
Topical Collection on Diabetes and Cardiovascular Disease
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose of Review This review summarizes recent cardiovascular outcome trials (CVOTs) with glucose-lowering drugs. Recent Findings The majority of recent CVOTs with glucose-lowering drugs have tested dipeptidyl peptidase-4 inhibitors (DPP4-i), glucagon-like peptide-1 receptors agonists (GLP1-RA), and sodium-glucose cotransporter 2 inhibitors (SGLT2i), but studies have also been performed with other agents including thiazolidinediones and insulin. Summary All CVOTs with DPP4-I, GLP1-RA, and SGLT2-i have demonstrated the cardiovascular (CV) safety of these agents compared to usual care. However, certain GLP1-RAs (liraglutide, subcutaneous semaglutide, albiglutide, dulaglutide) and SGLT2-i (empagliflozin, canagliflozin) have demonstrated a CV benefit, showing significant reductions in composite cardiovascular outcomes. Furthermore, all SGLT2-i also significantly decreased the risk for hospitalization for heart failure. Results from these studies have altered clinical guidelines worldwide and have resulted in new indications for some glucose-lowering drugs. In patients with T2D and high risk for CVD, GLP-1RA or SGLT2-i with proven cardiovascular benefit are recommended, irrespective of glycemic control.
ISSN:1523-3782
1534-3170
DOI:10.1007/s11886-021-01505-3